Patent · US Active

Formulations

US12162850B2 · kind B2 · utility

0Cited by

3References

33Claims

0Family size

Assignee

Betagenon AB · SE

Inventors

Thomas Edlund · Umeå, SE
Jacob Westman · Järlåsa, SE

Key dates

Filing date	May 15, 2023
Grant date	Dec 10, 2024
Priority date	—
Expiry date	May 15, 2043

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K9/4891
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

There is provided an alkali metal salt of 4-chloro-N-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide and formulations thereof. This salt finds particular utility in the treatment or prevention of a disorder or condition ameliorated by the activation of AMPK.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.